You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 10, October 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Laryngology/ Speech/ Language Pathology
 •Neoplasms of Head & Neck
 •Surgery
 •Surgical Oncology
 •Facial Plastic Surgery
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Role of Pectoralis Major Muscle Flap in Salvage Total Laryngectomy

Ziv Gil, MD, PhD; Amar Gupta, MD; Ben Kummer, MD; Peter G. Cordeiro, MD; Dennis H. Kraus, MD; Jatin P. Shah, MD; Snehal G. Patel, MD

Arch Otolaryngol Head Neck Surg. 2009;135(10):1019-1023.

Objective  To assess the utility of the pectoralis major muscle flap (PMMF) in patients undergoing salvage total laryngectomy.

Design  Retrospective cohort analysis.

Setting  Tertiary care cancer center.

Patients  The study included 461 patients who underwent laryngectomy. Eighty of them underwent salvage surgery with primary pharyngeal closure.

Interventions  Of the 80 patients, 69 (86%) underwent primary pharyngeal closure alone and 11 (14%) underwent a PMMF, which was used to buttress the pharyngeal suture line.

Main Outcome Measure  Two hundred thirty-six variables were recorded for each patient. Complications related to pharyngeal closure were measured.

Results  Sixty-four percent of the patients who underwent PMMF also underwent chemoradiation therapy as the initial definitive treatment compared with 25% in the non-PMMF group (P = .03). On multivariate analysis, chemoradiation therapy was the only independent predictor of pharyngocutaneous fistula formation (relative risk, 1.82; P = .02). Nevertheless, the pharyngocutaneous fistula rate was similar in the PMMF (27%) and the non-PMMF (24%) groups. Furthermore, similar durations of tube feeding, days to oral feeding, and hospitalization period were recorded in both groups.

Conclusion  The PMMF should be used judiciously as a surgical adjunct in high-risk patients, with the goal of minimizing the risk for the development of a pharyngocutaneous fistula.


Author Affiliations: Head and Neck Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. Dr Gil is now with the Skull Base Surgery Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.